Soligenix (SNGX) Competitors

$0.41 +0.05 (+13.01%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$0.40 -0.02 (-3.66%)

As of 05/14/2026 07:47 PM Eastern

SNGX vs. AIMD, BIVI, BCDA, GTBP, and CMMB

Should you buy Soligenix stock or one of its competitors? MarketBeat compares Soligenix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Soligenix include Ainos (AIMD), BioVie (BIVI), BioCardia (BCDA), GT Biopharma (GTBP), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry.

How does Soligenix compare to Ainos?

Soligenix (NASDAQ:SNGX) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Ainos is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	35.23	-$11.08M	-$1.68	N/A
Ainos	$120K	105.42	-$14.77M	-$2.89	N/A

Soligenix has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Ainos' return on equity of -144.01% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-244.73%	-131.22%
Ainos	-11,912.10%	-144.01%	-62.00%

Soligenix has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, Ainos has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market.

In the previous week, Ainos had 1 more articles in the media than Soligenix. MarketBeat recorded 5 mentions for Ainos and 4 mentions for Soligenix. Soligenix's average media sentiment score of 1.22 beat Ainos' score of 0.12 indicating that Soligenix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Soligenix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ainos	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Soligenix currently has a consensus price target of $6.00, indicating a potential upside of 1,363.41%. Given Soligenix's stronger consensus rating and higher possible upside, analysts clearly believe Soligenix is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

3.6% of Soligenix shares are owned by institutional investors. 3.1% of Soligenix shares are owned by insiders. Comparatively, 9.8% of Ainos shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Soligenix beats Ainos on 9 of the 15 factors compared between the two stocks.

How does Soligenix compare to BioVie?

Soligenix (NASDAQ:SNGX) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Soligenix presently has a consensus price target of $6.00, indicating a potential upside of 1,363.41%. Given Soligenix's stronger consensus rating and higher probable upside, analysts clearly believe Soligenix is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Soligenix has higher revenue and earnings than BioVie. BioVie is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	35.23	-$11.08M	-$1.68	N/A
BioVie	N/A	N/A	-$17.54M	-$3.25	N/A

BioVie's return on equity of -101.15% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-244.73%	-131.22%
BioVie	N/A	-101.15%	-90.18%

Soligenix has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, BioVie has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

3.6% of Soligenix shares are held by institutional investors. Comparatively, 4.6% of BioVie shares are held by institutional investors. 3.1% of Soligenix shares are held by insiders. Comparatively, 0.9% of BioVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Soligenix and Soligenix both had 4 articles in the media. BioVie's average media sentiment score of 1.47 beat Soligenix's score of 1.22 indicating that BioVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Soligenix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioVie	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Soligenix beats BioVie on 9 of the 13 factors compared between the two stocks.

How does Soligenix compare to BioCardia?

BioCardia (NASDAQ:BCDA) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

In the previous week, BioCardia had 1 more articles in the media than Soligenix. MarketBeat recorded 5 mentions for BioCardia and 4 mentions for Soligenix. Soligenix's average media sentiment score of 1.22 beat BioCardia's score of 0.78 indicating that Soligenix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCardia	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Soligenix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Soligenix's return on equity of -244.73% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-28,372.40%	-238.22%
Soligenix	N/A	-244.73%	-131.22%

20.6% of BioCardia shares are held by institutional investors. Comparatively, 3.6% of Soligenix shares are held by institutional investors. 17.4% of BioCardia shares are held by company insiders. Comparatively, 3.1% of Soligenix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BioCardia currently has a consensus price target of $25.00, suggesting a potential upside of 2,193.58%. Soligenix has a consensus price target of $6.00, suggesting a potential upside of 1,363.41%. Given BioCardia's higher possible upside, equities research analysts plainly believe BioCardia is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioCardia has higher earnings, but lower revenue than Soligenix. BioCardia is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	198.74	-$8.23M	-$1.29	N/A
Soligenix	$120K	35.23	-$11.08M	-$1.68	N/A

BioCardia has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Soligenix has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

Summary

BioCardia beats Soligenix on 7 of the 13 factors compared between the two stocks.

How does Soligenix compare to GT Biopharma?

Soligenix (NASDAQ:SNGX) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Soligenix has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

Soligenix presently has a consensus target price of $6.00, indicating a potential upside of 1,363.41%. Given Soligenix's stronger consensus rating and higher probable upside, research analysts clearly believe Soligenix is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, GT Biopharma had 4 more articles in the media than Soligenix. MarketBeat recorded 8 mentions for GT Biopharma and 4 mentions for Soligenix. Soligenix's average media sentiment score of 1.22 beat GT Biopharma's score of 0.96 indicating that Soligenix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Soligenix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GT Biopharma	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Soligenix has higher revenue and earnings than GT Biopharma. Soligenix is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	35.23	-$11.08M	-$1.68	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$6.55	N/A

3.6% of Soligenix shares are held by institutional investors. Comparatively, 8.2% of GT Biopharma shares are held by institutional investors. 3.1% of Soligenix shares are held by insiders. Comparatively, 3.4% of GT Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

GT Biopharma's return on equity of 0.00% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-244.73%	-131.22%
GT Biopharma	N/A	N/A	-116.67%

Summary

Soligenix beats GT Biopharma on 8 of the 14 factors compared between the two stocks.

How does Soligenix compare to Chemomab Therapeutics?

Chemomab Therapeutics (NASDAQ:CMMB) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Chemomab Therapeutics presently has a consensus target price of $25.00, suggesting a potential upside of 1,370.59%. Soligenix has a consensus target price of $6.00, suggesting a potential upside of 1,363.41%. Given Chemomab Therapeutics' higher probable upside, research analysts plainly believe Chemomab Therapeutics is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Chemomab Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Soligenix has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

Chemomab Therapeutics' return on equity of -103.85% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-103.85%	-90.44%
Soligenix	N/A	-244.73%	-131.22%

Chemomab Therapeutics has higher earnings, but lower revenue than Soligenix. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.56	N/A
Soligenix	$120K	35.23	-$11.08M	-$1.68	N/A

In the previous week, Chemomab Therapeutics had 1 more articles in the media than Soligenix. MarketBeat recorded 5 mentions for Chemomab Therapeutics and 4 mentions for Soligenix. Soligenix's average media sentiment score of 1.22 beat Chemomab Therapeutics' score of 0.62 indicating that Soligenix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemomab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Soligenix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

46.0% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Chemomab Therapeutics beats Soligenix on 7 of the 12 factors compared between the two stocks.

Get Soligenix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNGX vs. The Competition

Export

Metric	Soligenix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.74M	$3.42B	$6.34B	$12.37B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-0.24	18.47	20.66	25.63
Price / Sales	35.23	294.84	549.87	76.59
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	1.37	6.93	9.93	6.97
Net Income	-$11.08M	$24.11M	$3.55B	$333.62M
7 Day Performance	39.93%	5.89%	1.71%	1.09%
1 Month Performance	-64.35%	-0.91%	0.49%	3.08%
1 Year Performance	-78.42%	74.58%	39.41%	35.68%

Soligenix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNGX Soligenix	2.2409 of 5 stars	$0.41 +13.0%	$6.00 +1,363.4%	-78.4%	$3.74M	$120K	N/A	20	Positive News Earnings Report
AIMD Ainos	1.0597 of 5 stars	$1.73 +1.2%	N/A	-34.2%	$12.58M	$124.16K	N/A	40	News Coverage Earnings Report Gap Up
BIVI BioVie	0.9483 of 5 stars	$1.66 -3.7%	N/A	-87.5%	$12.49M	N/A	N/A	10	Earnings Report
BCDA BioCardia	4.1483 of 5 stars	$1.12 -1.3%	$25.00 +2,142.2%	-60.6%	$12.20M	N/A	N/A	40
GTBP GT Biopharma	1.3693 of 5 stars	$0.39 +0.7%	N/A	-80.0%	$12.15M	N/A	N/A	8	News Coverage Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNGX) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Soligenix (SNGX) Competitors